tetano
Editor, Senior Moderator
Clin Transplant Res
. 2024 Jun 21.
doi: 10.4285/ctr.24.0015. Online ahead of print. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis
Saeed Khorramnia[SUP] 1 [/SUP], Zia Navidi[SUP] 1 [/SUP], Amirhossein Orandi[SUP] 2 [/SUP], Mojgan Mohajeri Iravani[SUP] 3 [/SUP], Amirali Orandi[SUP] 4 [/SUP], Ebadallah Shiri Malekabad[SUP] 5 [/SUP], Seyed Hamid Pakzad Moghadam[SUP] 1 [/SUP]
Affiliations
Background: Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis against COVID-19 in this population.
Methods: We systematically searched the Cochrane Library, Web of Science, PubMed, and Embase databases to identify articles relevant to our study up to December 15, 2023. Comprehensive Meta-Analysis (ver. 3.0) was used for data analysis.
Results: The meta-analysis included seven eligible retrospective studies, encompassing a total of 4,026 SOTRs. The analysis revealed significant differences in SOTRs who received Tix/Cil preexposure prophylaxis relative to those who did not. Specifically, these differences were observed in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.15-0.60), hospitalization (OR, 0.24; 95% CI, 0.08-0.70), and intensive care unit admission (OR, 0.07; 95% CI, 0.02-0.22). However, mortality rate did not differ significantly between the two groups (P=0.06).
Conclusions: The evidence supporting the effectiveness of Tix/Cil as preexposure prophylaxis against SARS-CoV-2 in SOTRs is of a low to moderate level. Further high-quality research is necessary to understand its effects on this population.
Keywords: COVID-19; Cilgavimab and tixagevimab drug combination; Organ transplantation; Preexposure prophylaxis; SARS-CoV-2.
. 2024 Jun 21.
doi: 10.4285/ctr.24.0015. Online ahead of print. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis
Saeed Khorramnia[SUP] 1 [/SUP], Zia Navidi[SUP] 1 [/SUP], Amirhossein Orandi[SUP] 2 [/SUP], Mojgan Mohajeri Iravani[SUP] 3 [/SUP], Amirali Orandi[SUP] 4 [/SUP], Ebadallah Shiri Malekabad[SUP] 5 [/SUP], Seyed Hamid Pakzad Moghadam[SUP] 1 [/SUP]
Affiliations
- PMID: 38904088
- DOI: 10.4285/ctr.24.0015
Background: Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis against COVID-19 in this population.
Methods: We systematically searched the Cochrane Library, Web of Science, PubMed, and Embase databases to identify articles relevant to our study up to December 15, 2023. Comprehensive Meta-Analysis (ver. 3.0) was used for data analysis.
Results: The meta-analysis included seven eligible retrospective studies, encompassing a total of 4,026 SOTRs. The analysis revealed significant differences in SOTRs who received Tix/Cil preexposure prophylaxis relative to those who did not. Specifically, these differences were observed in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.15-0.60), hospitalization (OR, 0.24; 95% CI, 0.08-0.70), and intensive care unit admission (OR, 0.07; 95% CI, 0.02-0.22). However, mortality rate did not differ significantly between the two groups (P=0.06).
Conclusions: The evidence supporting the effectiveness of Tix/Cil as preexposure prophylaxis against SARS-CoV-2 in SOTRs is of a low to moderate level. Further high-quality research is necessary to understand its effects on this population.
Keywords: COVID-19; Cilgavimab and tixagevimab drug combination; Organ transplantation; Preexposure prophylaxis; SARS-CoV-2.